Cargando…

Apixaban compared with warfarin to prevent thrombosis in thrombotic antiphospholipid syndrome: a randomized trial

Thrombotic antiphospholipid syndrome (TAPS) is characterized by venous, arterial, or microvascular thrombosis. Patients with TAPS merit indefinite anticoagulation, and warfarin has historically been the standard treatment. Apixaban is an oral factor Xa inhibitor anticoagulant that requires no dose a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Woller, Scott C., Stevens, Scott M., Kaplan, David, Wang, Tzu-Fei, Branch, D. Ware, Groat, Danielle, Wilson, Emily L., Armbruster, Brent, Aston, Valerie T., Lloyd, James F., Rondina, Matthew T., Elliott, C. Greg
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society of Hematology 2022
Materias:	Clinical Trials and Observations
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8941474/ https://www.ncbi.nlm.nih.gov/pubmed/34662890 http://dx.doi.org/10.1182/bloodadvances.2021005808

Ejemplares similares

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM‐DVT): Methods of a prospective single‐arm management study
por: Woller, Scott C., et al.
Publicado: (2019)

Excluding pregnancy-associated deep vein thrombosis with whole-leg ultrasound
por: Parks, Anna L., et al.
Publicado: (2023)

A prognostic model (BATAP) with external validation for patients with transplant-associated thrombotic microangiopathy
por: Zhao, Peng, et al.
Publicado: (2021)

Direct oral anticoagulants in antiphospholipid syndrome with venous thromboembolism: Impact of the European Medicines Agency guidance
por: Fazili, Masarret, et al.
Publicado: (2019)

Rivaroxaban for the treatment of noncirrhotic splanchnic vein thrombosis: an interventional prospective cohort study
por: Ageno, Walter, et al.
Publicado: (2022)

Impaired fibrinolysis and increased clot strength are potential risk factors for thrombosis in lymphoma
por: Bønløkke, Søren Thorgaard, et al.
Publicado: (2023)

Incidence and risk factors associated with bleeding and thrombosis following chimeric antigen receptor T-cell therapy
por: Johnsrud, Andrew, et al.
Publicado: (2021)

Safety and effectiveness of apixaban compared to warfarin in dialysis patients
por: Reed, Daniel, et al.
Publicado: (2018)

Apixaban/heparin/warfarin: Treatment failure: case report
Publicado: (2021)

Dual Anticoagulation With Warfarin and Apixaban: A Case Report
por: Parker, Kristen, et al.
Publicado: (2022)

Adrenal Hemorrhage in a Patient Anticoagulated with Apixaban with Antiphospholipid Syndrome
por: Sanford, Zachary, et al.
Publicado: (2019)

Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation
por: Chan, Yi‐Hsin, et al.
Publicado: (2018)

Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation
por: Christersson, Christina, et al.
Publicado: (2019)

A comparison between warfarin and apixaban: A patient's perspective
por: Althemery, Abdullah U., et al.
Publicado: (2020)

Safety of apixaban and rivaroxaban compared to warfarin after cardiac surgery
por: Naik, Kushal D., et al.
Publicado: (2022)

Presumed antiphospholipid syndrome and thrombotic thrombocytopenic purpura: An infrequent association
por: Dolin, Hallie Hanna, et al.
Publicado: (2019)

Genetics InFormatics Trial (GIFT) of Warfarin to Prevent Deep Vein Thrombosis (DVT): Rationale and Study Design
por: Do, Elizabeth J., et al.
Publicado: (2011)

Decreased parasite burden and altered host response in children with sickle cell anemia and severe anemia with malaria
por: Henrici, Ryan C., et al.
Publicado: (2021)

Rationale and design of the impact of anticoagulation therapy on the Cognitive Decline and Dementia in Patients with Nonvalvular Atrial Fibrillation (CAF) Trial: A Vanguard study
por: Bunch, T. Jared, et al.
Publicado: (2019)

Clinical Management of Thrombotic Antiphospholipid Syndrome
por: Tumian, Nor Rafeah, et al.
Publicado: (2022)

Cost-Effectiveness of Apixaban Compared with Warfarin for Stroke Prevention in Atrial Fibrillation
por: Lee, Soyon, et al.
Publicado: (2012)

Non-major bleeding with apixaban versus warfarin in patients with atrial fibrillation
por: Bahit, M Cecilia, et al.
Publicado: (2017)

Apixaban vs. Warfarin in Atrial Fibrillation Patients With Chronic Kidney Disease
por: Fu, Chung-Ming, et al.
Publicado: (2021)

Comparing the Efficacy and Safety of Apixaban Versus Warfarin in Morbidly Obese Patients
por: Alotaibi, Sultan N, et al.
Publicado: (2022)

Long-term survival with sickle cell disease: a nationwide cohort study of Medicare and Medicaid beneficiaries
por: Jiao, Boshen, et al.
Publicado: (2023)

Antiphospholipid antibodies and thrombosis: pathogenesis of antiphospholipid syndrome
por: Koike, T
Publicado: (2003)

Zinc for infection prevention in children with sickle cell anemia: a randomized double-blind placebo-controlled trial
por: Namazzi, Ruth, et al.
Publicado: (2023)

Effects of low-dose aspirin and heparin on the pregnancy outcome in women with antiphospholipid syndrome
por: Baiazid, Latifa, et al.
Publicado: (2022)

Evaluation of Apixaban in Patients With Antiphospholipid Syndrome: A Case Series and Review of Literature
por: Al Sulaiman, Khalid, et al.
Publicado: (2022)

Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE
por: Cohen, H, et al.
Publicado: (2015)

Evidence for an Inherited Contribution to Sepsis Susceptibility Among a Cohort of U.S. Veterans
por: Kempker, Jordan A., et al.
Publicado: (2022)

Unraveling the pathophysiology of lower-limb postthrombotic syndrome in adolescents: a proof-of-concept study
por: Avila, M. Laura, et al.
Publicado: (2023)

Phase 2 study of PD-1 blockade following autologous transplantation for patients with AML ineligible for allogeneic transplant
por: Solomon, Scott R., et al.
Publicado: (2023)

Differences in Antiphospholipid Antibody Profile between Patients with Obstetric and Thrombotic Antiphospholipid Syndrome
por: Anunciación-Llunell, Ariadna, et al.
Publicado: (2022)

Switching from rivaroxaban to warfarin: an open label pharmacodynamic study in healthy subjects
por: Moore, Kenneth Todd, et al.
Publicado: (2015)

Economic Evaluation of Warfarin, Dabigatran, Rivaroxaban, and Apixaban for Stroke Prevention in Atrial Fibrillation
por: Wisløff, Torbjørn, et al.
Publicado: (2014)

Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation
por: Yao, Xiaoxi, et al.
Publicado: (2016)

Resolution of a warfarin and dabigatran-resistant left atrial appendage thrombus with apixaban
por: Miwa, Yosuke, et al.
Publicado: (2016)

High mortality from Plasmodium falciparum malaria in children living with sickle cell anemia on the coast of Kenya
por: McAuley, Charlotte F., et al.
Publicado: (2010)

A real-world study of combined modality therapy for early-stage Hodgkin lymphoma: too little treatment impacts outcome
por: Chohan, Karan L., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p6n27ehoi8h68tlro6pt5kge32